Christina Chambers
Concepts (764)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 85 | 2026 | 609 | 15.670 |
Why?
| | Fetal Alcohol Spectrum Disorders | 46 | 2026 | 74 | 11.820 |
Why?
| | Pregnancy Outcome | 57 | 2026 | 503 | 10.090 |
Why?
| | Pregnancy | 248 | 2026 | 7230 | 8.160 |
Why?
| | Milk, Human | 24 | 2025 | 176 | 8.100 |
Why?
| | Prenatal Exposure Delayed Effects | 59 | 2026 | 665 | 7.980 |
Why?
| | Premature Birth | 47 | 2026 | 390 | 7.930 |
Why?
| | Breast Feeding | 27 | 2025 | 447 | 5.070 |
Why?
| | Abnormalities, Drug-Induced | 24 | 2026 | 38 | 5.060 |
Why?
| | Alcohol Drinking | 34 | 2026 | 850 | 4.410 |
Why?
| | Antidepressive Agents | 14 | 2025 | 235 | 4.100 |
Why?
| | California | 50 | 2026 | 475 | 3.870 |
Why?
| | Rheumatic Diseases | 14 | 2025 | 101 | 3.620 |
Why?
| | Infant, Newborn | 104 | 2026 | 6460 | 3.470 |
Why?
| | Autoimmune Diseases | 12 | 2025 | 467 | 3.220 |
Why?
| | Congenital Abnormalities | 17 | 2024 | 108 | 3.180 |
Why?
| | Female | 300 | 2026 | 79499 | 3.160 |
Why?
| | Maternal Exposure | 13 | 2021 | 189 | 3.080 |
Why?
| | Abortion, Spontaneous | 14 | 2022 | 120 | 3.040 |
Why?
| | Lactation | 19 | 2025 | 193 | 2.830 |
Why?
| | Infant, Small for Gestational Age | 17 | 2026 | 118 | 2.750 |
Why?
| | Teratogens | 12 | 2025 | 25 | 2.650 |
Why?
| | Antiphospholipid Syndrome | 3 | 2025 | 37 | 2.460 |
Why?
| | Humans | 316 | 2026 | 146342 | 2.370 |
Why?
| | Arthritis, Rheumatoid | 11 | 2023 | 1185 | 2.210 |
Why?
| | Mothers | 18 | 2025 | 772 | 2.150 |
Why?
| | Gestational Age | 34 | 2026 | 990 | 2.110 |
Why?
| | Adult | 136 | 2026 | 41087 | 2.100 |
Why?
| | Lupus Erythematosus, Systemic | 7 | 2026 | 241 | 2.080 |
Why?
| | Pre-Eclampsia | 11 | 2026 | 206 | 1.990 |
Why?
| | Influenza Vaccines | 9 | 2017 | 544 | 1.990 |
Why?
| | Infant | 73 | 2025 | 10114 | 1.970 |
Why?
| | Cohort Studies | 47 | 2026 | 6077 | 1.970 |
Why?
| | Asthma | 19 | 2024 | 1800 | 1.930 |
Why?
| | Antirheumatic Agents | 10 | 2025 | 309 | 1.930 |
Why?
| | Hypertension, Pregnancy-Induced | 7 | 2023 | 69 | 1.810 |
Why?
| | Prospective Studies | 47 | 2026 | 8123 | 1.790 |
Why?
| | Risk Factors | 67 | 2026 | 10921 | 1.780 |
Why?
| | Child Development | 14 | 2026 | 481 | 1.650 |
Why?
| | Anti-Inflammatory Agents | 5 | 2025 | 474 | 1.630 |
Why?
| | Analgesics, Non-Narcotic | 4 | 2026 | 129 | 1.580 |
Why?
| | Drug Hypersensitivity | 2 | 2026 | 93 | 1.580 |
Why?
| | Canada | 13 | 2025 | 432 | 1.520 |
Why?
| | Depression | 12 | 2024 | 1575 | 1.380 |
Why?
| | Glucocorticoids | 5 | 2022 | 536 | 1.350 |
Why?
| | Antiemetics | 2 | 2026 | 51 | 1.340 |
Why?
| | Pregnancy Complications, Cardiovascular | 4 | 2026 | 83 | 1.300 |
Why?
| | Anti-Asthmatic Agents | 11 | 2019 | 263 | 1.290 |
Why?
| | Young Adult | 58 | 2026 | 14330 | 1.270 |
Why?
| | Gastroschisis | 6 | 2018 | 32 | 1.250 |
Why?
| | Influenza, Human | 8 | 2019 | 640 | 1.180 |
Why?
| | Dietary Supplements | 10 | 2021 | 587 | 1.170 |
Why?
| | Hypersensitivity | 4 | 2024 | 253 | 1.150 |
Why?
| | Oligosaccharides | 3 | 2025 | 62 | 1.140 |
Why?
| | Biological Products | 6 | 2026 | 258 | 1.140 |
Why?
| | Ethanol | 17 | 2024 | 630 | 1.130 |
Why?
| | Pregnancy Trimester, Second | 7 | 2019 | 91 | 1.130 |
Why?
| | Pregnancy Complications, Infectious | 10 | 2026 | 438 | 1.120 |
Why?
| | Acetaminophen | 5 | 2024 | 268 | 1.110 |
Why?
| | Arthritis, Juvenile | 2 | 2019 | 64 | 1.110 |
Why?
| | Colitis, Ulcerative | 3 | 2025 | 143 | 1.050 |
Why?
| | Cardiovascular Diseases | 5 | 2026 | 2219 | 1.050 |
Why?
| | Contraception | 5 | 2020 | 170 | 1.040 |
Why?
| | Lupus Nephritis | 2 | 2025 | 67 | 1.040 |
Why?
| | Research | 3 | 2021 | 421 | 1.030 |
Why?
| | Case-Control Studies | 25 | 2024 | 3647 | 1.030 |
Why?
| | Substance-Related Disorders | 9 | 2026 | 1100 | 1.030 |
Why?
| | Hemangioma | 2 | 2018 | 46 | 1.020 |
Why?
| | Indians, North American | 3 | 2019 | 527 | 1.010 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2025 | 50 | 1.010 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2019 | 162 | 1.000 |
Why?
| | Hydroxychloroquine | 3 | 2023 | 65 | 0.980 |
Why?
| | Birth Weight | 14 | 2026 | 521 | 0.980 |
Why?
| | Hypothermia, Induced | 2 | 2025 | 96 | 0.970 |
Why?
| | Heart Defects, Congenital | 11 | 2026 | 923 | 0.970 |
Why?
| | Morning Sickness | 1 | 2026 | 3 | 0.950 |
Why?
| | Child | 50 | 2026 | 22693 | 0.950 |
Why?
| | Product Surveillance, Postmarketing | 5 | 2024 | 74 | 0.940 |
Why?
| | Crohn Disease | 3 | 2025 | 250 | 0.920 |
Why?
| | Marijuana Use | 5 | 2024 | 218 | 0.920 |
Why?
| | Marijuana Abuse | 3 | 2026 | 217 | 0.910 |
Why?
| | Chorioamnionitis | 2 | 2024 | 50 | 0.910 |
Why?
| | Nausea | 1 | 2026 | 111 | 0.900 |
Why?
| | Hyperemesis Gravidarum | 1 | 2025 | 6 | 0.890 |
Why?
| | Vomiting | 1 | 2026 | 131 | 0.880 |
Why?
| | Infant, Low Birth Weight | 7 | 2026 | 154 | 0.880 |
Why?
| | United States | 33 | 2026 | 16136 | 0.870 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.870 |
Why?
| | Coronavirus Infections | 2 | 2020 | 379 | 0.870 |
Why?
| | Drug Therapy | 2 | 2016 | 85 | 0.870 |
Why?
| | Sudden Infant Death | 2 | 2024 | 39 | 0.870 |
Why?
| | Birth Certificates | 1 | 2024 | 12 | 0.860 |
Why?
| | Depressive Disorder | 5 | 2025 | 361 | 0.860 |
Why?
| | Gastrointestinal Agents | 1 | 2025 | 63 | 0.850 |
Why?
| | Psychotherapy, Brief | 2 | 2015 | 44 | 0.850 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2024 | 415 | 0.810 |
Why?
| | Bulimia Nervosa | 1 | 2024 | 20 | 0.810 |
Why?
| | Nicotine | 4 | 2026 | 337 | 0.800 |
Why?
| | Crotonates | 2 | 2023 | 7 | 0.790 |
Why?
| | Toluidines | 2 | 2023 | 10 | 0.790 |
Why?
| | Hydroxybutyrates | 2 | 2023 | 15 | 0.790 |
Why?
| | Prenatal Care | 11 | 2023 | 310 | 0.790 |
Why?
| | Infant, Newborn, Diseases | 3 | 2021 | 113 | 0.780 |
Why?
| | Risk | 12 | 2020 | 920 | 0.770 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 6 | 2025 | 266 | 0.770 |
Why?
| | Teratology | 3 | 2020 | 3 | 0.760 |
Why?
| | Child, Preschool | 27 | 2026 | 11913 | 0.750 |
Why?
| | Cognition | 5 | 2025 | 1292 | 0.750 |
Why?
| | Retrospective Studies | 32 | 2026 | 17438 | 0.750 |
Why?
| | Plasmalogens | 1 | 2022 | 7 | 0.740 |
Why?
| | Strabismus | 1 | 2023 | 71 | 0.740 |
Why?
| | Anorexia Nervosa | 1 | 2023 | 82 | 0.730 |
Why?
| | Anemia | 1 | 2024 | 190 | 0.720 |
Why?
| | Cannabis | 6 | 2025 | 521 | 0.710 |
Why?
| | Nitriles | 2 | 2023 | 212 | 0.710 |
Why?
| | Prevalence | 13 | 2022 | 2861 | 0.700 |
Why?
| | Male | 76 | 2026 | 73396 | 0.690 |
Why?
| | Metformin | 1 | 2025 | 328 | 0.680 |
Why?
| | Inflammatory Bowel Diseases | 4 | 2019 | 352 | 0.670 |
Why?
| | Research Design | 4 | 2025 | 1143 | 0.670 |
Why?
| | Registries | 9 | 2025 | 2400 | 0.660 |
Why?
| | Hypothermia | 1 | 2021 | 53 | 0.660 |
Why?
| | Isoxazoles | 4 | 2012 | 57 | 0.650 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2016 | 132 | 0.640 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.640 |
Why?
| | Risk Assessment | 18 | 2025 | 3712 | 0.640 |
Why?
| | Data Collection | 6 | 2023 | 650 | 0.630 |
Why?
| | Interviews as Topic | 6 | 2026 | 930 | 0.630 |
Why?
| | Paternity | 2 | 2012 | 5 | 0.630 |
Why?
| | Brain Diseases | 1 | 2021 | 159 | 0.620 |
Why?
| | Prednisone | 2 | 2018 | 229 | 0.610 |
Why?
| | Oseltamivir | 2 | 2019 | 17 | 0.610 |
Why?
| | Dyssomnias | 1 | 2019 | 4 | 0.610 |
Why?
| | Ukraine | 16 | 2022 | 37 | 0.610 |
Why?
| | Population Surveillance | 5 | 2019 | 481 | 0.610 |
Why?
| | Medical Records | 2 | 2017 | 193 | 0.600 |
Why?
| | Central Nervous System Depressants | 5 | 2020 | 83 | 0.600 |
Why?
| | Adalimumab | 1 | 2019 | 53 | 0.600 |
Why?
| | Adolescent | 43 | 2026 | 22557 | 0.590 |
Why?
| | Maternal-Fetal Exchange | 6 | 2022 | 171 | 0.590 |
Why?
| | Live Birth | 6 | 2023 | 81 | 0.580 |
Why?
| | Fever | 4 | 2011 | 322 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 992 | 0.570 |
Why?
| | Infant, Premature, Diseases | 4 | 2022 | 113 | 0.570 |
Why?
| | Arthritis | 1 | 2019 | 97 | 0.560 |
Why?
| | Migraine Disorders | 1 | 2020 | 109 | 0.560 |
Why?
| | Biological Specimen Banks | 1 | 2020 | 137 | 0.560 |
Why?
| | Nonprescription Drugs | 2 | 2017 | 68 | 0.560 |
Why?
| | Deprescriptions | 1 | 2019 | 38 | 0.550 |
Why?
| | Telephone | 2 | 2016 | 175 | 0.550 |
Why?
| | Referral and Consultation | 2 | 2015 | 881 | 0.550 |
Why?
| | Patient Selection | 3 | 2021 | 728 | 0.550 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2026 | 422 | 0.550 |
Why?
| | Infant Mortality | 5 | 2024 | 127 | 0.540 |
Why?
| | Postpartum Period | 5 | 2023 | 377 | 0.540 |
Why?
| | Socioeconomic Factors | 11 | 2024 | 1327 | 0.530 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 829 | 0.530 |
Why?
| | Neonatal Screening | 3 | 2024 | 185 | 0.530 |
Why?
| | Immunologic Factors | 3 | 2016 | 244 | 0.530 |
Why?
| | Logistic Models | 14 | 2020 | 2126 | 0.520 |
Why?
| | Mouth Abnormalities | 1 | 2017 | 3 | 0.520 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5899 | 0.520 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2021 | 2022 | 0.510 |
Why?
| | Folic Acid | 2 | 2017 | 197 | 0.510 |
Why?
| | Infant, Premature | 9 | 2026 | 622 | 0.510 |
Why?
| | Substance Abuse Detection | 2 | 2018 | 110 | 0.510 |
Why?
| | RNA, Viral | 2 | 2022 | 693 | 0.510 |
Why?
| | Maternal Age | 7 | 2025 | 129 | 0.510 |
Why?
| | Probability | 1 | 2018 | 309 | 0.510 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1412 | 0.500 |
Why?
| | Brain | 4 | 2024 | 2991 | 0.500 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 160 | 0.500 |
Why?
| | Aminosalicylic Acids | 1 | 2016 | 10 | 0.490 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2012 | 44 | 0.490 |
Why?
| | Physical Examination | 4 | 2023 | 237 | 0.490 |
Why?
| | Odds Ratio | 8 | 2023 | 1077 | 0.490 |
Why?
| | Models, Statistical | 4 | 2018 | 669 | 0.490 |
Why?
| | Poverty | 6 | 2020 | 530 | 0.480 |
Why?
| | Severity of Illness Index | 11 | 2025 | 2921 | 0.480 |
Why?
| | Adrenal Cortex Hormones | 5 | 2026 | 486 | 0.480 |
Why?
| | Multiple Sclerosis | 2 | 2019 | 435 | 0.470 |
Why?
| | Self Report | 3 | 2019 | 870 | 0.470 |
Why?
| | Drug Prescriptions | 1 | 2018 | 314 | 0.470 |
Why?
| | Cannabinoids | 1 | 2018 | 182 | 0.470 |
Why?
| | Hydrocortisone | 1 | 2018 | 303 | 0.460 |
Why?
| | Nasal Decongestants | 1 | 2015 | 9 | 0.460 |
Why?
| | Public Health | 2 | 2019 | 574 | 0.460 |
Why?
| | Motivational Interviewing | 1 | 2017 | 121 | 0.460 |
Why?
| | Aluminum Hydroxide | 1 | 2015 | 13 | 0.450 |
Why?
| | Contraceptives, Oral | 1 | 2015 | 37 | 0.450 |
Why?
| | Information Services | 4 | 2020 | 42 | 0.440 |
Why?
| | Lipid A | 1 | 2015 | 27 | 0.440 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1064 | 0.430 |
Why?
| | Decision Support Techniques | 3 | 2026 | 478 | 0.430 |
Why?
| | Medical Records Systems, Computerized | 1 | 2015 | 95 | 0.430 |
Why?
| | Pain | 2 | 2022 | 790 | 0.430 |
Why?
| | Fatty Acids | 2 | 2020 | 460 | 0.430 |
Why?
| | Pandemics | 2 | 2020 | 1707 | 0.420 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 185 | 0.420 |
Why?
| | Vaccination | 6 | 2025 | 1449 | 0.410 |
Why?
| | Physician's Role | 2 | 2016 | 225 | 0.410 |
Why?
| | Pregnancy Trimester, First | 5 | 2026 | 140 | 0.410 |
Why?
| | Vitamins | 1 | 2015 | 183 | 0.410 |
Why?
| | Maternal Behavior | 4 | 2020 | 83 | 0.400 |
Why?
| | Anti-Bacterial Agents | 3 | 2023 | 1942 | 0.400 |
Why?
| | Biomarkers | 10 | 2026 | 4340 | 0.400 |
Why?
| | Dyspnea | 1 | 2016 | 251 | 0.400 |
Why?
| | Preconception Care | 6 | 2025 | 50 | 0.400 |
Why?
| | Monte Carlo Method | 1 | 2014 | 151 | 0.390 |
Why?
| | Growth Disorders | 2 | 2012 | 89 | 0.390 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2025 | 81 | 0.390 |
Why?
| | Fetal Growth Retardation | 7 | 2023 | 592 | 0.390 |
Why?
| | Placenta | 6 | 2023 | 794 | 0.390 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1591 | 0.380 |
Why?
| | Neuropsychological Tests | 7 | 2023 | 1149 | 0.380 |
Why?
| | Environmental Exposure | 6 | 2025 | 578 | 0.370 |
Why?
| | Hospitalization | 9 | 2024 | 2475 | 0.360 |
Why?
| | Neurodevelopmental Disorders | 5 | 2020 | 239 | 0.350 |
Why?
| | Counseling | 1 | 2015 | 406 | 0.350 |
Why?
| | Developmental Disabilities | 4 | 2024 | 281 | 0.350 |
Why?
| | Propensity Score | 1 | 2014 | 376 | 0.350 |
Why?
| | Environmental Pollutants | 2 | 2025 | 143 | 0.340 |
Why?
| | Papillomavirus Vaccines | 1 | 2015 | 296 | 0.340 |
Why?
| | Stroke | 1 | 2020 | 1287 | 0.330 |
Why?
| | Child Behavior | 3 | 2026 | 234 | 0.330 |
Why?
| | Medicaid | 3 | 2022 | 477 | 0.330 |
Why?
| | Critical Pathways | 4 | 2019 | 104 | 0.330 |
Why?
| | Anxiety | 4 | 2024 | 1125 | 0.330 |
Why?
| | Program Development | 1 | 2013 | 371 | 0.320 |
Why?
| | Etanercept | 2 | 2022 | 60 | 0.320 |
Why?
| | Longitudinal Studies | 10 | 2026 | 3017 | 0.320 |
Why?
| | Electronic Health Records | 2 | 2017 | 1210 | 0.320 |
Why?
| | Decision Making | 1 | 2018 | 993 | 0.310 |
Why?
| | Alcoholic Intoxication | 1 | 2011 | 78 | 0.310 |
Why?
| | United States Food and Drug Administration | 4 | 2020 | 208 | 0.300 |
Why?
| | MicroRNAs | 3 | 2023 | 699 | 0.300 |
Why?
| | Perinatal Mortality | 2 | 2024 | 23 | 0.300 |
Why?
| | Likelihood Functions | 3 | 2018 | 138 | 0.290 |
Why?
| | Lipid Metabolism | 1 | 2013 | 533 | 0.290 |
Why?
| | Fertility Preservation | 2 | 2020 | 57 | 0.290 |
Why?
| | Mobile Applications | 2 | 2022 | 196 | 0.290 |
Why?
| | Psoriasis | 1 | 2010 | 110 | 0.290 |
Why?
| | Face | 2 | 2026 | 177 | 0.280 |
Why?
| | Prenatal Diagnosis | 4 | 2018 | 190 | 0.280 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 78 | 0.280 |
Why?
| | Antiviral Agents | 3 | 2024 | 779 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 1224 | 0.280 |
Why?
| | Musculoskeletal Diseases | 2 | 2020 | 95 | 0.280 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1543 | 0.280 |
Why?
| | Drug Labeling | 2 | 2020 | 37 | 0.270 |
Why?
| | Problem Behavior | 2 | 2020 | 97 | 0.270 |
Why?
| | Gastroenterology | 3 | 2019 | 187 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 931 | 0.270 |
Why?
| | Frontal Lobe | 1 | 2009 | 159 | 0.270 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1331 | 0.270 |
Why?
| | Drug Information Services | 1 | 2007 | 11 | 0.270 |
Why?
| | Interpersonal Relations | 1 | 2011 | 387 | 0.270 |
Why?
| | Pharmacokinetics | 1 | 2007 | 33 | 0.270 |
Why?
| | Fetus | 7 | 2018 | 800 | 0.260 |
Why?
| | Stress, Psychological | 3 | 2024 | 1171 | 0.260 |
Why?
| | Patient Care Planning | 2 | 2019 | 170 | 0.260 |
Why?
| | Linear Models | 4 | 2023 | 857 | 0.250 |
Why?
| | Alcoholism | 5 | 2021 | 830 | 0.250 |
Why?
| | Embryo, Mammalian | 1 | 2007 | 230 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2026 | 1408 | 0.250 |
Why?
| | Lipids | 2 | 2025 | 714 | 0.240 |
Why?
| | Surveys and Questionnaires | 13 | 2026 | 6073 | 0.240 |
Why?
| | Nails | 1 | 2026 | 14 | 0.240 |
Why?
| | Baths | 1 | 2006 | 14 | 0.240 |
Why?
| | Fetal Development | 3 | 2018 | 297 | 0.240 |
Why?
| | alpha-Fetoproteins | 3 | 2016 | 42 | 0.240 |
Why?
| | Dicyclomine | 1 | 2026 | 1 | 0.240 |
Why?
| | Doxylamine | 1 | 2026 | 3 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2488 | 0.240 |
Why?
| | Infant Death | 2 | 2023 | 9 | 0.240 |
Why?
| | Pregnancy Trimester, Third | 3 | 2020 | 117 | 0.230 |
Why?
| | Maternal Health | 4 | 2024 | 50 | 0.230 |
Why?
| | Pyridoxine | 1 | 2026 | 37 | 0.230 |
Why?
| | Cesarean Section | 3 | 2023 | 230 | 0.230 |
Why?
| | Risk Evaluation and Mitigation | 1 | 2025 | 1 | 0.230 |
Why?
| | Anti-Allergic Agents | 1 | 2006 | 41 | 0.230 |
Why?
| | Cognitive Science | 1 | 2025 | 4 | 0.220 |
Why?
| | C-Peptide | 2 | 2018 | 191 | 0.220 |
Why?
| | Capillaries | 1 | 2026 | 123 | 0.220 |
Why?
| | Fluoxetine | 2 | 2011 | 56 | 0.220 |
Why?
| | Endocrine Disruptors | 1 | 2025 | 42 | 0.220 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2025 | 17 | 0.220 |
Why?
| | Women's Health | 1 | 2007 | 317 | 0.220 |
Why?
| | Incidence | 5 | 2026 | 2936 | 0.220 |
Why?
| | Reproductive Health | 3 | 2022 | 94 | 0.220 |
Why?
| | Reproduction | 2 | 2025 | 209 | 0.220 |
Why?
| | Body Mass Index | 4 | 2023 | 2458 | 0.220 |
Why?
| | Twins | 1 | 2006 | 156 | 0.220 |
Why?
| | Milk Proteins | 1 | 2025 | 33 | 0.220 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1512 | 0.220 |
Why?
| | Mammary Glands, Human | 1 | 2025 | 71 | 0.220 |
Why?
| | Child Behavior Disorders | 1 | 2026 | 117 | 0.210 |
Why?
| | Prescription Drugs | 2 | 2017 | 110 | 0.210 |
Why?
| | Unemployment | 1 | 2024 | 43 | 0.210 |
Why?
| | Neuropsychology | 1 | 2025 | 44 | 0.210 |
Why?
| | Drug Combinations | 1 | 2026 | 400 | 0.210 |
Why?
| | Carbohydrates | 1 | 2025 | 66 | 0.210 |
Why?
| | Mammary Glands, Animal | 1 | 2025 | 124 | 0.210 |
Why?
| | Pregnancy Trimesters | 5 | 2018 | 20 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2024 | 45 | 0.210 |
Why?
| | Treatment Outcome | 8 | 2025 | 11821 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2024 | 733 | 0.210 |
Why?
| | Residence Characteristics | 3 | 2020 | 385 | 0.210 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2018 | 2623 | 0.210 |
Why?
| | Protective Factors | 1 | 2024 | 97 | 0.210 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2024 | 44 | 0.210 |
Why?
| | Checklist | 1 | 2025 | 105 | 0.200 |
Why?
| | Medical Record Linkage | 1 | 2024 | 68 | 0.200 |
Why?
| | Family | 2 | 2023 | 690 | 0.200 |
Why?
| | Heart Rate | 4 | 2022 | 846 | 0.200 |
Why?
| | Oligohydramnios | 1 | 2023 | 15 | 0.200 |
Why?
| | Apolipoproteins E | 1 | 2024 | 97 | 0.200 |
Why?
| | Social Class | 3 | 2020 | 260 | 0.200 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 35 | 0.200 |
Why?
| | Eclampsia | 2 | 2021 | 6 | 0.200 |
Why?
| | Retinopathy of Prematurity | 1 | 2026 | 183 | 0.200 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5439 | 0.200 |
Why?
| | Penicillins | 1 | 2023 | 65 | 0.200 |
Why?
| | Pleurisy | 1 | 2023 | 6 | 0.190 |
Why?
| | Diet | 3 | 2017 | 1273 | 0.190 |
Why?
| | Thinness | 1 | 2023 | 100 | 0.190 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 87 | 0.190 |
Why?
| | Tetralogy of Fallot | 1 | 2024 | 76 | 0.190 |
Why?
| | Databases, Factual | 6 | 2020 | 1493 | 0.190 |
Why?
| | Educational Status | 3 | 2020 | 466 | 0.190 |
Why?
| | Middle Aged | 11 | 2020 | 36619 | 0.190 |
Why?
| | Alanine | 1 | 2024 | 171 | 0.190 |
Why?
| | Wireless Technology | 1 | 2022 | 18 | 0.190 |
Why?
| | Reaction Time | 2 | 2021 | 438 | 0.190 |
Why?
| | Fetal Death | 1 | 2002 | 59 | 0.180 |
Why?
| | Saliva | 1 | 2024 | 256 | 0.180 |
Why?
| | Antibodies, Viral | 2 | 2024 | 689 | 0.180 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2022 | 28 | 0.180 |
Why?
| | Gaucher Disease | 1 | 2022 | 4 | 0.180 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.180 |
Why?
| | Microcephaly | 3 | 2016 | 106 | 0.180 |
Why?
| | Fluorocarbons | 1 | 2023 | 122 | 0.180 |
Why?
| | Mastitis | 1 | 2022 | 6 | 0.180 |
Why?
| | Administration, Oral | 3 | 2026 | 872 | 0.180 |
Why?
| | Appetite Depressants | 1 | 2002 | 19 | 0.180 |
Why?
| | Pilot Projects | 4 | 2021 | 1888 | 0.180 |
Why?
| | Phentermine | 1 | 2002 | 14 | 0.180 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 17 | 0.180 |
Why?
| | Neural Tube Defects | 4 | 2016 | 67 | 0.180 |
Why?
| | Disease Management | 3 | 2021 | 651 | 0.180 |
Why?
| | Universities | 1 | 2024 | 451 | 0.180 |
Why?
| | Fenfluramine | 1 | 2002 | 20 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2025 | 666 | 0.170 |
Why?
| | Overweight | 3 | 2022 | 614 | 0.170 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 183 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 712 | 0.170 |
Why?
| | Choline | 3 | 2019 | 136 | 0.170 |
Why?
| | Central Nervous System Agents | 1 | 2021 | 7 | 0.170 |
Why?
| | Rheumatology | 2 | 2020 | 136 | 0.170 |
Why?
| | Fetal Diseases | 2 | 2018 | 192 | 0.170 |
Why?
| | Delphi Technique | 4 | 2025 | 350 | 0.170 |
Why?
| | Discrimination Learning | 1 | 2021 | 53 | 0.170 |
Why?
| | Paternal Exposure | 1 | 2021 | 1 | 0.170 |
Why?
| | Stillbirth | 4 | 2026 | 83 | 0.170 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 307 | 0.170 |
Why?
| | Ultrasonography, Prenatal | 2 | 2016 | 291 | 0.170 |
Why?
| | Biological Factors | 1 | 2021 | 39 | 0.160 |
Why?
| | Cannabidiol | 1 | 2023 | 142 | 0.160 |
Why?
| | Pasteurization | 1 | 2020 | 3 | 0.160 |
Why?
| | Infant Behavior | 1 | 2021 | 28 | 0.160 |
Why?
| | Psychotropic Drugs | 1 | 2021 | 75 | 0.160 |
Why?
| | Immune System Diseases | 1 | 2021 | 43 | 0.160 |
Why?
| | Psychomotor Performance | 3 | 2020 | 329 | 0.160 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 31 | 0.160 |
Why?
| | Teratogenesis | 2 | 2018 | 2 | 0.160 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2020 | 8 | 0.160 |
Why?
| | Heart Block | 2 | 2018 | 41 | 0.160 |
Why?
| | Alemtuzumab | 1 | 2020 | 15 | 0.160 |
Why?
| | Age Factors | 4 | 2018 | 3347 | 0.160 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2021 | 39 | 0.160 |
Why?
| | Hypertension | 2 | 2019 | 1272 | 0.160 |
Why?
| | Regression Analysis | 2 | 2020 | 999 | 0.160 |
Why?
| | Term Birth | 2 | 2018 | 25 | 0.160 |
Why?
| | Mental Health | 2 | 2024 | 779 | 0.160 |
Why?
| | Abruptio Placentae | 1 | 2019 | 6 | 0.150 |
Why?
| | Marriage | 1 | 2021 | 122 | 0.150 |
Why?
| | Pediatrics | 2 | 2016 | 1124 | 0.150 |
Why?
| | Placenta Diseases | 2 | 2017 | 20 | 0.150 |
Why?
| | Circadian Rhythm | 1 | 2024 | 515 | 0.150 |
Why?
| | Postpartum Hemorrhage | 1 | 2020 | 28 | 0.150 |
Why?
| | Southwestern United States | 1 | 2019 | 93 | 0.150 |
Why?
| | Pro-Opiomelanocortin | 1 | 2019 | 20 | 0.150 |
Why?
| | Micronutrients | 2 | 2021 | 102 | 0.150 |
Why?
| | Health Personnel | 1 | 2026 | 754 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 43 | 0.150 |
Why?
| | Weight Gain | 2 | 2022 | 562 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 26 | 0.150 |
Why?
| | Period Circadian Proteins | 1 | 2019 | 33 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 66 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 406 | 0.150 |
Why?
| | Cities | 1 | 2019 | 140 | 0.140 |
Why?
| | Mood Disorders | 1 | 2020 | 130 | 0.140 |
Why?
| | Prognosis | 3 | 2017 | 4351 | 0.140 |
Why?
| | Zika Virus | 1 | 2020 | 137 | 0.140 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2019 | 48 | 0.140 |
Why?
| | Placentation | 1 | 2019 | 52 | 0.140 |
Why?
| | Health Behavior | 3 | 2017 | 802 | 0.140 |
Why?
| | Memory Disorders | 1 | 2020 | 198 | 0.140 |
Why?
| | Circulating MicroRNA | 1 | 2019 | 26 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1150 | 0.140 |
Why?
| | Certolizumab Pegol | 1 | 2018 | 5 | 0.140 |
Why?
| | Smoking | 2 | 2020 | 1486 | 0.140 |
Why?
| | Executive Function | 2 | 2021 | 463 | 0.140 |
Why?
| | Pain Measurement | 1 | 2021 | 573 | 0.140 |
Why?
| | Algorithms | 4 | 2022 | 1849 | 0.140 |
Why?
| | Immune System | 1 | 2020 | 181 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.140 |
Why?
| | Organic Chemicals | 1 | 2019 | 113 | 0.140 |
Why?
| | Intellectual Disability | 1 | 2020 | 183 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 178 | 0.140 |
Why?
| | Depression, Postpartum | 1 | 2020 | 117 | 0.140 |
Why?
| | Clinical Competence | 1 | 2006 | 1272 | 0.130 |
Why?
| | Fetal Macrosomia | 1 | 2018 | 64 | 0.130 |
Why?
| | Zika Virus Infection | 1 | 2020 | 174 | 0.130 |
Why?
| | Food Supply | 2 | 2017 | 94 | 0.130 |
Why?
| | Precision Medicine | 1 | 2022 | 462 | 0.130 |
Why?
| | Peptides | 1 | 2024 | 992 | 0.130 |
Why?
| | Selection Bias | 1 | 2018 | 38 | 0.130 |
Why?
| | Animals | 14 | 2025 | 38107 | 0.130 |
Why?
| | Benzodiazepines | 1 | 2019 | 158 | 0.130 |
Why?
| | Electrocardiography | 2 | 2022 | 667 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 305 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 2 | 2019 | 516 | 0.130 |
Why?
| | Vasculitis | 1 | 2018 | 69 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 200 | 0.130 |
Why?
| | Alaska | 1 | 2017 | 74 | 0.130 |
Why?
| | Virus Replication | 1 | 2020 | 526 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 365 | 0.130 |
Why?
| | Vaccines, Inactivated | 1 | 2017 | 71 | 0.130 |
Why?
| | Albuterol | 1 | 2017 | 76 | 0.130 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 132 | 0.130 |
Why?
| | Fertilization in Vitro | 1 | 2018 | 109 | 0.130 |
Why?
| | Hemangioma, Capillary | 1 | 2017 | 14 | 0.130 |
Why?
| | Suicidal Ideation | 1 | 2023 | 543 | 0.130 |
Why?
| | Maternal Health Services | 1 | 2019 | 100 | 0.130 |
Why?
| | Vascular Neoplasms | 1 | 2017 | 19 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 59 | 0.130 |
Why?
| | Ibuprofen | 1 | 2017 | 87 | 0.120 |
Why?
| | Pneumonia | 1 | 2023 | 635 | 0.120 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2017 | 85 | 0.120 |
Why?
| | Air Pollution, Radioactive | 1 | 2016 | 2 | 0.120 |
Why?
| | Cesium Radioisotopes | 1 | 2016 | 4 | 0.120 |
Why?
| | Public Health Surveillance | 1 | 2017 | 84 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1537 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2018 | 184 | 0.120 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2016 | 5 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2019 | 223 | 0.120 |
Why?
| | Analgesics, Opioid | 2 | 2026 | 1221 | 0.120 |
Why?
| | Cost of Illness | 1 | 2019 | 323 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.120 |
Why?
| | Sepsis | 1 | 2023 | 669 | 0.120 |
Why?
| | Epidemiological Monitoring | 2 | 2013 | 70 | 0.120 |
Why?
| | Air Pollution | 1 | 2020 | 314 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2018 | 248 | 0.120 |
Why?
| | Habituation, Psychophysiologic | 1 | 2016 | 58 | 0.120 |
Why?
| | Growth | 1 | 2016 | 48 | 0.120 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 119 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2081 | 0.110 |
Why?
| | Patient Discharge | 1 | 2022 | 997 | 0.110 |
Why?
| | Republic of Korea | 1 | 2015 | 43 | 0.110 |
Why?
| | Immunization | 2 | 2015 | 376 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2016 | 73 | 0.110 |
Why?
| | Social Determinants of Health | 1 | 2020 | 317 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2016 | 279 | 0.110 |
Why?
| | Mental Processes | 1 | 2015 | 38 | 0.110 |
Why?
| | Geography | 2 | 2019 | 187 | 0.110 |
Why?
| | Indians, South American | 1 | 2015 | 23 | 0.110 |
Why?
| | Air Pollutants | 1 | 2020 | 406 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2018 | 429 | 0.110 |
Why?
| | Food Services | 1 | 2015 | 20 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1164 | 0.110 |
Why?
| | Underage Drinking | 1 | 2015 | 22 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 322 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 725 | 0.110 |
Why?
| | Echocardiography | 1 | 2018 | 645 | 0.110 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 189 | 0.110 |
Why?
| | Genetic Testing | 3 | 2024 | 492 | 0.110 |
Why?
| | Mental Recall | 1 | 2016 | 226 | 0.100 |
Why?
| | Drug Utilization | 1 | 2015 | 171 | 0.100 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 55 | 0.100 |
Why?
| | Sex Characteristics | 3 | 2016 | 801 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 545 | 0.100 |
Why?
| | United Kingdom | 1 | 2015 | 377 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 265 | 0.100 |
Why?
| | Comorbidity | 4 | 2020 | 1665 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 344 | 0.100 |
Why?
| | Fertility | 1 | 2015 | 174 | 0.100 |
Why?
| | Computer Simulation | 1 | 2018 | 1014 | 0.100 |
Why?
| | Obesity | 4 | 2022 | 3131 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 346 | 0.100 |
Why?
| | Disease Progression | 2 | 2019 | 2867 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2021 | 2791 | 0.100 |
Why?
| | Environment Design | 1 | 2013 | 26 | 0.100 |
Why?
| | Chickenpox | 1 | 1994 | 83 | 0.090 |
Why?
| | Energy Intake | 1 | 2016 | 507 | 0.090 |
Why?
| | Motivation | 1 | 2017 | 605 | 0.090 |
Why?
| | Heart | 1 | 2016 | 626 | 0.090 |
Why?
| | Lung Diseases | 1 | 2019 | 787 | 0.090 |
Why?
| | Internationality | 1 | 2013 | 156 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1325 | 0.090 |
Why?
| | Half-Life | 1 | 2012 | 157 | 0.090 |
Why?
| | Lip | 1 | 2012 | 23 | 0.090 |
Why?
| | Risk-Taking | 1 | 2015 | 321 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1998 | 0.090 |
Why?
| | Linoleic Acid | 1 | 2012 | 44 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 490 | 0.080 |
Why?
| | Carbamazepine | 1 | 2011 | 24 | 0.080 |
Why?
| | Interview, Psychological | 1 | 2011 | 94 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 881 | 0.080 |
Why?
| | Sample Size | 1 | 2011 | 124 | 0.080 |
Why?
| | Fathers | 1 | 2011 | 53 | 0.080 |
Why?
| | Recurrence | 3 | 2020 | 1133 | 0.080 |
Why?
| | Sexual Partners | 1 | 2012 | 195 | 0.080 |
Why?
| | Fetal Blood | 2 | 2023 | 325 | 0.080 |
Why?
| | Body Height | 1 | 2012 | 205 | 0.080 |
Why?
| | Head | 1 | 2012 | 125 | 0.080 |
Why?
| | Cholestyramine Resin | 1 | 2010 | 6 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2015 | 770 | 0.080 |
Why?
| | Perception | 1 | 2013 | 373 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1500 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 511 | 0.080 |
Why?
| | Tretinoin | 1 | 2011 | 115 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2011 | 125 | 0.080 |
Why?
| | Dietary Fats | 1 | 2012 | 307 | 0.080 |
Why?
| | Behavior Therapy | 1 | 2013 | 291 | 0.080 |
Why?
| | Body Size | 1 | 2010 | 91 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 970 | 0.070 |
Why?
| | Cephalometry | 1 | 2009 | 30 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2012 | 561 | 0.070 |
Why?
| | Time Factors | 3 | 2018 | 7109 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1408 | 0.070 |
Why?
| | Adrenergic beta-Agonists | 2 | 2006 | 91 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18297 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1036 | 0.070 |
Why?
| | Anticholesteremic Agents | 1 | 2010 | 156 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2011 | 253 | 0.070 |
Why?
| | Liver | 1 | 2017 | 1864 | 0.070 |
Why?
| | Stakeholder Participation | 2 | 2019 | 90 | 0.070 |
Why?
| | Information Dissemination | 2 | 2007 | 226 | 0.070 |
Why?
| | Embryonic Development | 1 | 2009 | 124 | 0.070 |
Why?
| | Internet | 1 | 2013 | 660 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2919 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 6034 | 0.070 |
Why?
| | Patient Compliance | 2 | 2016 | 589 | 0.070 |
Why?
| | Tosyl Compounds | 1 | 2007 | 17 | 0.060 |
Why?
| | Leukotriene Antagonists | 1 | 2007 | 24 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1354 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3206 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1148 | 0.060 |
Why?
| | Microscopic Angioscopy | 1 | 2026 | 1 | 0.060 |
Why?
| | Early Diagnosis | 2 | 2019 | 251 | 0.060 |
Why?
| | Moscow | 1 | 2006 | 1 | 0.060 |
Why?
| | Acetates | 1 | 2007 | 78 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 612 | 0.060 |
Why?
| | Karyotyping | 1 | 2006 | 106 | 0.060 |
Why?
| | Nutrition Surveys | 2 | 2019 | 270 | 0.060 |
Why?
| | Transcriptome | 2 | 2023 | 1068 | 0.060 |
Why?
| | Halogenated Diphenyl Ethers | 1 | 2025 | 7 | 0.060 |
Why?
| | Theophylline | 1 | 2006 | 41 | 0.060 |
Why?
| | Parabens | 1 | 2025 | 11 | 0.060 |
Why?
| | Latin America | 1 | 2006 | 96 | 0.060 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2025 | 21 | 0.060 |
Why?
| | Temperance | 1 | 2005 | 20 | 0.060 |
Why?
| | Diet Surveys | 1 | 2006 | 89 | 0.060 |
Why?
| | Isotretinoin | 1 | 2005 | 27 | 0.060 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2025 | 29 | 0.060 |
Why?
| | Social Welfare | 1 | 2005 | 26 | 0.060 |
Why?
| | Quinolines | 1 | 2007 | 191 | 0.060 |
Why?
| | Multilingualism | 1 | 2005 | 31 | 0.060 |
Why?
| | Acculturation | 1 | 2005 | 55 | 0.060 |
Why?
| | Alcoholic Beverages | 1 | 2005 | 32 | 0.060 |
Why?
| | Pesticides | 1 | 2025 | 59 | 0.060 |
Why?
| | Body Temperature | 1 | 2006 | 228 | 0.060 |
Why?
| | Perinatal Care | 2 | 2016 | 61 | 0.060 |
Why?
| | Dermatologic Agents | 1 | 2005 | 69 | 0.050 |
Why?
| | Insulin | 1 | 2016 | 2525 | 0.050 |
Why?
| | Phenols | 1 | 2025 | 106 | 0.050 |
Why?
| | Colorado | 1 | 2015 | 4595 | 0.050 |
Why?
| | CLOCK Proteins | 1 | 2024 | 9 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2021 | 2537 | 0.050 |
Why?
| | Transient Tachypnea of the Newborn | 1 | 2024 | 1 | 0.050 |
Why?
| | Carnitine | 1 | 2024 | 91 | 0.050 |
Why?
| | Glucosyltransferases | 1 | 2023 | 4 | 0.050 |
Why?
| | Perinatal Death | 1 | 2024 | 26 | 0.050 |
Why?
| | Circadian Clocks | 1 | 2024 | 59 | 0.050 |
Why?
| | Mutation | 1 | 2015 | 4093 | 0.050 |
Why?
| | Allergy and Immunology | 1 | 2024 | 42 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2025 | 330 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 467 | 0.050 |
Why?
| | Urinary Tract Infections | 2 | 2016 | 209 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2113 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 368 | 0.050 |
Why?
| | Safety | 3 | 2014 | 347 | 0.050 |
Why?
| | Haplotypes | 1 | 2024 | 506 | 0.050 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2024 | 104 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2599 | 0.050 |
Why?
| | Tooth, Deciduous | 1 | 2022 | 19 | 0.050 |
Why?
| | Infant Health | 1 | 2022 | 24 | 0.050 |
Why?
| | Craniosynostoses | 1 | 2003 | 69 | 0.050 |
Why?
| | Glucosylceramidase | 1 | 2022 | 5 | 0.050 |
Why?
| | Causality | 1 | 2023 | 128 | 0.050 |
Why?
| | Enzyme Replacement Therapy | 1 | 2022 | 15 | 0.050 |
Why?
| | Bias | 1 | 2023 | 197 | 0.040 |
Why?
| | Focus Groups | 1 | 2025 | 588 | 0.040 |
Why?
| | Genome, Human | 1 | 2024 | 431 | 0.040 |
Why?
| | Endocardial Cushions | 1 | 2022 | 7 | 0.040 |
Why?
| | Adenosine | 1 | 2024 | 256 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 588 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 2022 | 105 | 0.040 |
Why?
| | Learning | 2 | 2016 | 446 | 0.040 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 373 | 0.040 |
Why?
| | Rats | 2 | 2021 | 5586 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 205 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 295 | 0.040 |
Why?
| | Mercaptopurine | 1 | 2020 | 15 | 0.040 |
Why?
| | Exercise | 1 | 2013 | 2213 | 0.040 |
Why?
| | Nervous System | 1 | 2021 | 68 | 0.040 |
Why?
| | Cell Movement | 1 | 2025 | 951 | 0.040 |
Why?
| | Organizations | 1 | 2020 | 28 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 43 | 0.040 |
Why?
| | Hysterectomy | 1 | 2021 | 139 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2020 | 36 | 0.040 |
Why?
| | ROC Curve | 1 | 2022 | 617 | 0.040 |
Why?
| | Chromosomes, Human, X | 1 | 2020 | 76 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 453 | 0.040 |
Why?
| | Truncus Arteriosus, Persistent | 1 | 2019 | 7 | 0.040 |
Why?
| | Sex Factors | 1 | 2026 | 2107 | 0.040 |
Why?
| | Lipotropic Agents | 1 | 2019 | 5 | 0.040 |
Why?
| | Halogenation | 1 | 2019 | 22 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2019 | 19 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 390 | 0.040 |
Why?
| | Transposition of Great Vessels | 1 | 2019 | 41 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 124 | 0.040 |
Why?
| | Norway | 1 | 2019 | 41 | 0.040 |
Why?
| | Communication Disorders | 1 | 2019 | 14 | 0.040 |
Why?
| | Motor Disorders | 1 | 2019 | 17 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 64 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2021 | 358 | 0.030 |
Why?
| | Inpatients | 1 | 2023 | 540 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2021 | 320 | 0.030 |
Why?
| | Pharmacovigilance | 1 | 2018 | 25 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2021 | 276 | 0.030 |
Why?
| | Postnatal Care | 1 | 2019 | 76 | 0.030 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.030 |
Why?
| | Antibodies, Antinuclear | 1 | 2018 | 60 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2019 | 188 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 901 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 2018 | 39 | 0.030 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 24 | 0.030 |
Why?
| | Sampling Studies | 1 | 2018 | 97 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 102 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1219 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 200 | 0.030 |
Why?
| | Thrombosis | 1 | 2021 | 398 | 0.030 |
Why?
| | Infant, Postmature | 1 | 2017 | 1 | 0.030 |
Why?
| | Chemokines | 1 | 2018 | 217 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 133 | 0.030 |
Why?
| | Food Assistance | 1 | 2017 | 34 | 0.030 |
Why?
| | Fertilization | 1 | 2017 | 44 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2020 | 422 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 219 | 0.030 |
Why?
| | Forecasting | 1 | 2019 | 388 | 0.030 |
Why?
| | Microphthalmos | 1 | 2016 | 2 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2020 | 354 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2017 | 35 | 0.030 |
Why?
| | Sweden | 1 | 2017 | 114 | 0.030 |
Why?
| | Obstetrics | 1 | 2019 | 179 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 164 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 426 | 0.030 |
Why?
| | Bacteria | 1 | 2022 | 766 | 0.030 |
Why?
| | Parity | 1 | 2017 | 113 | 0.030 |
Why?
| | Metabolomics | 1 | 2022 | 738 | 0.030 |
Why?
| | Fruit | 1 | 2017 | 144 | 0.030 |
Why?
| | Birth Intervals | 1 | 2016 | 23 | 0.030 |
Why?
| | Trophoblasts | 1 | 2019 | 219 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 159 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2240 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 298 | 0.030 |
Why?
| | Nutrition Assessment | 1 | 2016 | 90 | 0.030 |
Why?
| | Sunlight | 1 | 2017 | 78 | 0.030 |
Why?
| | Sarcosine | 1 | 2015 | 10 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 375 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 908 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1271 | 0.030 |
Why?
| | Beijing | 1 | 2015 | 2 | 0.030 |
Why?
| | Insurance, Health | 1 | 2018 | 318 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 226 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2016 | 265 | 0.030 |
Why?
| | Personality Disorders | 1 | 2016 | 79 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 310 | 0.030 |
Why?
| | Acoustic Stimulation | 1 | 2016 | 325 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2017 | 379 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 196 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2015 | 329 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8391 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 974 | 0.030 |
Why?
| | Memory | 1 | 2016 | 298 | 0.030 |
Why?
| | Seasons | 1 | 2017 | 540 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 725 | 0.030 |
Why?
| | Communication | 1 | 2020 | 980 | 0.020 |
Why?
| | Public Facilities | 1 | 2013 | 3 | 0.020 |
Why?
| | Biopsy | 1 | 2017 | 1075 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1827 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4580 | 0.020 |
Why?
| | Vitamin D | 1 | 2017 | 402 | 0.020 |
Why?
| | Recreation | 1 | 2013 | 27 | 0.020 |
Why?
| | Transportation | 1 | 2013 | 54 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 163 | 0.020 |
Why?
| | Patient Care Team | 1 | 2019 | 701 | 0.020 |
Why?
| | Chondrodysplasia Punctata | 1 | 2012 | 1 | 0.020 |
Why?
| | Spina Bifida Occulta | 1 | 2012 | 3 | 0.020 |
Why?
| | Virus Diseases | 1 | 2015 | 219 | 0.020 |
Why?
| | Ectodermal Dysplasia | 1 | 2012 | 16 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 561 | 0.020 |
Why?
| | Housing | 1 | 2013 | 142 | 0.020 |
Why?
| | Pierre Robin Syndrome | 1 | 2012 | 16 | 0.020 |
Why?
| | Bicycling | 1 | 2013 | 117 | 0.020 |
Why?
| | Schools | 1 | 2015 | 436 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1503 | 0.020 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2012 | 49 | 0.020 |
Why?
| | Schizophrenia | 1 | 2016 | 537 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2070 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2502 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2363 | 0.020 |
Why?
| | Zanamivir | 1 | 2011 | 2 | 0.020 |
Why?
| | Patient Safety | 1 | 2015 | 352 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3545 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1763 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1761 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 91 | 0.020 |
Why?
| | Self Disclosure | 1 | 2008 | 62 | 0.020 |
Why?
| | Sex Determination Analysis | 1 | 2008 | 10 | 0.020 |
Why?
| | Maternal Welfare | 1 | 2008 | 22 | 0.020 |
Why?
| | Biomedical Research | 1 | 2015 | 729 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1101 | 0.020 |
Why?
| | Phenylcarbamates | 1 | 2007 | 5 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2007 | 83 | 0.020 |
Why?
| | Aged | 2 | 2017 | 26432 | 0.020 |
Why?
| | Societies, Medical | 1 | 2011 | 907 | 0.010 |
Why?
| | Sulfides | 1 | 2007 | 92 | 0.010 |
Why?
| | Pregnancy Tests | 1 | 2005 | 11 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1298 | 0.010 |
Why?
| | Hotlines | 1 | 2004 | 35 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2005 | 567 | 0.010 |
Why?
| | Occipital Bone | 1 | 2003 | 18 | 0.010 |
Why?
| | Supine Position | 1 | 2003 | 39 | 0.010 |
Why?
| | Child Language | 1 | 2003 | 21 | 0.010 |
Why?
| | Indoles | 1 | 2007 | 511 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 594 | 0.010 |
Why?
| | Skull | 1 | 2003 | 162 | 0.010 |
Why?
| | Radiography | 1 | 2003 | 861 | 0.010 |
Why?
| | Sleep | 1 | 2003 | 896 | 0.010 |
Why?
|
|
Chambers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|